151. Role of intestinal microbiota in transplantation outcomes.
- Author
-
Taur Y, Jenq RR, Ubeda C, van den Brink M, and Pamer EG
- Subjects
- Anti-Bacterial Agents administration & dosage, Anti-Bacterial Agents adverse effects, Antineoplastic Agents therapeutic use, Bacteremia etiology, Bacteremia microbiology, Bacteremia mortality, Clinical Trials as Topic, Graft vs Host Disease microbiology, Graft vs Host Disease mortality, Graft vs Host Disease pathology, Hematologic Neoplasms microbiology, Hematologic Neoplasms mortality, Hematologic Neoplasms pathology, Humans, Metronidazole administration & dosage, Metronidazole adverse effects, Opportunistic Infections etiology, Opportunistic Infections microbiology, Opportunistic Infections mortality, Risk Factors, Survival Analysis, Vancomycin administration & dosage, Vancomycin adverse effects, Vancomycin-Resistant Enterococci growth & development, Vancomycin-Resistant Enterococci pathogenicity, Bacteremia drug therapy, Gastrointestinal Microbiome, Graft vs Host Disease prevention & control, Hematologic Neoplasms therapy, Hematopoietic Stem Cell Transplantation mortality, Opportunistic Infections drug therapy
- Abstract
While allogeneic hematopoietic stem cell transplantations have a curative potential, infections and graft-versus-host disease remain significant problems. The intestinal microbiota can influence responses to cancer chemotherapy and the role of the microbiota in affecting allogeneic hematopoietic stem cell transplantation outcomes is increasingly appreciated. The following paper discusses the most recent developments in this area., (Copyright © 2015 Elsevier Ltd. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF